Test drug BP1001 with venetoclax and decitabine for AML
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 or older).
- Have AML confirmed by a bone marrow test or biopsy, including newly diagnosed, secondary AML, or relapsed/refractory AML.
- Your doctor must believe you can take venetoclax and decitabine, and that intensive chemotherapy is not a good option for you.
- Your white blood cell (WBC) count must be 25 or less (in the trial’s lab units) at the start; leukapheresis or hydroxyurea is allowed to lower it if needed.
- Your heart, liver, and kidney function must be good enough (including kidney function with eGFR ≥ 40).
- You must be able to do study treatment (ECOG body-function score 0–2) and recover from any recent procedures or prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different intensities of venetoclax (a targeted pill) combined with standard chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The goal is to find out which dose works better and is safer.
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.